- An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells
-
Park YH, Kim HW, Kim HS, Nam ST, Lee D, Lee MB, Min KY, Koo J, Kim SJ, Kim YM, Kim HS, Choi WS
- KMID: 2447858
- Biomol Ther.
- 2019 May;27(3):311-317.
- doi: 10.4062/biomolther.2018.148
Mast cells are the most prominent effector cells of Type 1 hypersensitivity immune responses. CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory... -
- CITED
-
- Close
- SHARE
-
- Close
